Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Halal & cGMP Certified
This study was funded by the National Natural Science Foundation of China (82374525), Scientific Research Project of the Education Department of Hunan Province (22A0250), Hunan Provincial Clinical Medical Research Center for Ophthalmic Diseases (Traditional Chinese Medicine) (2023SK4038), Key Scientific Research Project of Hunan Administration of Traditional Chinese Medicine (C2023013), Project on Advancing Clinical Evidence - based Capacity for Traditional Chinese Medicine - treated Diseases with Advantages (JBGS-A1-02) and Graduate Innovation Project of Hunan University of Chinese Medicine (2024CX025)
Clin Cancer Res, 2020
Data from the Phase 3 MAESTRO-NAFLD-1 trial demonstrated that resmetirom, an oral liver-targeted thyroid hormone receptor- selective agonist, significantly improves the atherogenic lipid/lipoprotein profile in patients with presumed NASH
.png?ver=1765877054)
Nevertheless, the development of an efficient GPx mimic for countering radiation toxicity may also face challenges like non-targeted radioprotection in cancerous cells, poor bioavailability, and poor metabolic stability [39]
US$ 25.69
US$ 27.38
US$ 29.87
US$ 28.16
US$ 28.31
US$ 20.71
US$ 20.85
US$ 24.27
US$ 29.39
US$ 20.11
US$ 23.25
